Elite Pharmaceuticals launches generic methadone tablets
Elite Pharmaceuticals Inc. (OTCQB: ELTP) announced the commercial launch of its generic methadone hydrochloride tablets in 5 mg and 10 mg strengths.
The tablets are indicated for managing severe and persistent pain requiring opioid analgesics when alternative treatment options, including immediate-release opioids, are inadequate. The medication is also approved for detoxification and maintenance treatment of opioid addiction when used with appropriate social and medical services.
According to IQVIA data cited by the company, brand and generic methadone products generated approximately $22 million in annual retail sales in 2025.
Elite Pharmaceuticals operates as a specialty pharmaceutical company focused on developing and distributing niche generic products. The company specializes in oral, controlled-release drug products and operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, New Jersey.
The company distributes multiple generic products nationwide under the Elite Laboratories Inc. label and has additional products licensed to TAGI Pharma.
You May Also Be Interested In
- SEC files civil complaint against Netcapital and certain individuals
- L3Harris opens $6M naval training facility in Providence, R.I.
- Trump: Leavitt Will Be Departing Her Role
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share